株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

細胞治療の世界市場:主要企業と取り組み (2018年)

Global Cell Therapy Market - Companies to Action, 2018

発行 Frost & Sullivan 商品コード 808221
出版日 ページ情報 英文 88 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.95円で換算しております。
Back to Top
細胞治療の世界市場:主要企業と取り組み (2018年) Global Cell Therapy Market - Companies to Action, 2018
出版日: 2019年03月11日 ページ情報: 英文 88 Pages
概要

幹細胞、CAR-T細胞、併用療法に焦点を当てたコラボレーティブビジネスモデルが世界の細胞治療市場の成長を推進する見通しです。

当レポートでは、世界の細胞治療市場と主要企業の取り組みを調査し、市場の定義と概要、細胞治療のバリューチェーン、ベンダーのエコシステム、主なティアI・II・III企業のプロファイル・取り組みなどをまとめています。

第1章 エグゼクティブサマリー

第2章 企業と取り組み 概要

  • 企業と取り組み:価値の創出者
  • 市場機会と脅威

第3章 細胞治療:市場概要

  • 市場の定義
  • 市場区分
  • 細胞治療のバリューチェーン
  • ベンダーのエコシステム
  • インフルエンサーの影響
  • 三大動向とベンダー戦略
  • 細胞治療:ベンダー環境

第4章 主要企業のプロファイル:ティアI

  • Juno Therapeutics
  • bluebird bio
  • Kite Pharma
  • Adaptimmune
  • Oxford BioMedica
  • JCR 医薬品
    • 概要
    • 技術プラットフォーム
    • 提携・合意
    • 事例・近年の展開、など

第5章 主要企業のプロファイル:ティアII

  • Sangamo Therapeutics
  • DiscGenics
  • TiGenix
  • Bone Therapeutics
  • Cell Medica
  • Mesoblast
  • Cynata Therapeutics
  • Medipost
  • Anterogen
  • Pharmicell
    • 企業概要
    • 提供価値

第6章 主要企業のプロファイル:ティアIII

  • デジタルパソロジー企業のショートプロファイル

第7章 成長機会・推奨行動

  • エコシステムのトランスフォーメーション
  • 成長機会
  • 成長の必須要件

第8章 総論

第9章 付録

第10章 FROST & SULLIVANについて

目次
Product Code: PA16-52

A Collaborative Business Model With Focus on Stem Cells, Chimeric Antigen Receptor T (CAR-T) Cells and Combination Therapies Will Propel Market Growth

The global pharmaceutical industry is continuously evolving. with the rising need for novel therapies in the ever-changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as continuously growing number of cancer cases, market needs are shifting from traditional, small molecules to novel, large-molecule therapies, with cell therapies dominating the space. The study on the "Global Cell Therapy Market, 2018, Companies to Action” presents an overview of the global cell therapy landscape, with an emphasis on the key game-changing companies disrupting this market. The study highlights the emerging companies across regions that support the development and manufacturing of novel cell therapies.

With the changing market landscape, big pharma and biopharma participants, are looking toward the adoption of a collaborative business approach by either entering into co-development and/or co-commercialization agreements or acquiring smaller, niche participants so as to achieve a competitive advantage with respect to a specific therapy area or technology. The study also delves into some of the leading strategies adopted by market participants in order to succeed in this highly dynamic market. In addition to the above-mentioned strategic analysis, information such as risk sharing and fast to market business models of some of the emerging business models across the cell therapy market is also provided.

Research Highlights:

This study identifies some of the strategies adopted by these game-changing companies with respect to key market-growth opportunities such as the use of combination therapies, manufacturing advancement and automation, adoption of newer gene-editing technologies such as CRISPR/Cas9, and so on. The study also highlights some collaborations and partnerships between these disruptive participants and throws some light on their upcoming drug pipeline; thereby, highlighting their contribution to this market. Additionally, it gives an insight into the leading strategic imperatives shaping the global industry and its long-term implication on market growth.

Key Issues Addressed:

  • What are the key market opportunities in the global cell therapy market?
  • What is the impact of external industry environment on market growth?
  • Which are some of the unique participants that are introducing cutting-edge therapies in this segment?
  • What are the strategic imperatives to be adopted by these participants to bring about this market transformation?
  • What is the growth potential of this rapidly expanding cell therapy market?
  • What are some key factors for success in the global cell therapy market?

Table of Contents

1. EXECUTIVE SUMMARY

  • Key Findings-Analysis of Companies to Action
  • Key Findings-Analysis of Companies to Action (continued)
  • Scope and Segmentation
  • Key Questions Addressed in this Study

2. COMPANIES TO ACTION OVERVIEW

  • Companies to Action Value Creators
  • Opportunities and Threats

3. CELL THERAPY MARKET OVERVIEW

  • Market Definitions
  • Market Segmentation
  • Cell Therapy Value Chain
  • Vendor Ecosystem
  • Impact of Key Market Influencers
  • Top 3 Trends and Vendor Strategies
  • Key Market Participants Aligned with Top 3 Trends
  • Cell Therapy-Vendor Landscape

4. C2A PROFILES-TIER I

  • Juno Therapeutics-Overview
  • Juno Therapeutics-Technology Platforms
  • Juno Therapeutics-Major Partnerships and Agreements
  • bluebird bio-Business Overview
  • bluebird bio-Technology Platform
  • bluebird bio-Major Partnerships and Agreements
  • Kite Pharma-Overview
  • Kite Pharma-Key Technology/ Product/Services
  • Kite Pharma-Case Example and Recent Developments
  • Adaptimmune-Overview
  • Adaptimmune-Technology Platforms
  • Adaptimmune-Case Example and Recent Developments
  • Oxford BioMedica-Overview
  • Oxford BioMedica-Technology Platform
  • Oxford BioMedica-Case Example and Recent Developments
  • JCR Pharmaceuticals-Overview
  • JCR Pharmaceuticals-Technology Platforms
  • JCR Pharmaceuticals-Case Example and Recent Developments

5. C2A PROFILES-TIER II

  • Sangamo Therapeutics-Company Overview
  • Sangamo Therapeutics-Value Proposition
  • DiscGenics-Company Overview
  • DiscGenics-Value Proposition
  • TiGenix-Company Overview
  • TiGenix-Value Proposition
  • Bone Therapeutics-Company Overview
  • Bone Therapeutics-Value Proposition
  • Cell Medica-Company Overview
  • Cell Medica-Value Proposition
  • Mesoblast-Company Overview
  • Mesoblast-Value Proposition
  • Cynata Therapeutics-Company Overview
  • Cynata Therapeutics-Value Proposition
  • Medipost-Company Overview
  • Medipost-Value Proposition
  • Anterogen-Company Overview
  • Anterogen-Value Proposition
  • Pharmicell-Company Overview
  • Pharmicell-Value Proposition

6. C2A PROFILES-TIER III

  • Short Profiles of Digital Pathology Companies
  • Short Profiles of Digital Pathology Companies (continued)
  • Short Profiles of Digital Pathology Companies (continued)
  • Short Profiles of Digital Pathology Companies (continued)

7. GROWTH OPPORTUNITIES AND COMPANIES TO ACTION

  • Transformation in the Industry Ecosystem
  • Five Major Growth Opportunities
  • Strategic Imperatives for Growth

8. THE LAST WORD

  • Conclusion-Key Takeaways
  • Legal Disclaimer

9. APPENDIX

  • Abbreviation List
  • List of Exhibits
  • List of Exhibits (continued)

10. THE FROST & SULLIVAN STORY

  • The Frost & Sullivan Story
  • Value Proposition-Future of Your Company & Career
  • Global Perspective
  • Industry Convergence
  • 360° Research Perspective
  • Implementation Excellence
  • Our Blue Ocean Strategy
Back to Top